Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712459 · ClinicalTrials.gov registry record
Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
A clinical trial of Transformed Splenic Marginal Zone Lymphoma, sponsored by International Extranodal Lymphoma Study Group (IELSG).
- Recruiting
- Registry status
- 100
- Enrollment target
- 7
- Study locations
NCT06712459 is a study of Transformed Splenic Marginal Zone Lymphoma that is actively recruiting participants, run by International Extranodal Lymphoma Study Group (IELSG). The registered enrollment target is 100 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT06712459, a study of Transformed Splenic Marginal Zone Lymphoma, is actively recruiting participants, sponsored by International Extranodal Lymphoma Study Group (IELSG).
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 7
- Study locations
Study Summary
Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
Conditions Studied
Study Locations (7)
Other
- Universitz Hospitals Leuven - Leuven
- Hôpital Saint Louis - Paris
- Fondazione IRCCS Policlinico San Matteo - Pavia
- Hospital Clínic de Barcelona - Barcelona
- Oncology Institute of Southern Switzerland - Bellinzona
- University Hospitals Dorset - Bournemouth
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2029-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06712459
The ClinicalTrials.gov registry entry for NCT06712459 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Extranodal Lymphoma Study Group (IELSG), which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transformed Splenic Marginal Zone Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT06712459 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.
Frequently Asked Questions
What is clinical trial NCT06712459 about?
NCT06712459 is a clinical study titled "Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma". Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is know...
What is the current status of trial NCT06712459?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-10-13. Estimated completion is 2029-03.
What conditions does trial NCT06712459 study?
This clinical trial studies the following conditions: Transformed Splenic Marginal Zone Lymphoma.
Who is sponsoring clinical trial NCT06712459?
This trial is sponsored by International Extranodal Lymphoma Study Group (IELSG), which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712459 being conducted?
This trial has 7 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.